Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects such as cytomegalovirus (CMV), following its failure to reach the primary ...
Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of ...
Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.
Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...
Researchers have identified in a new study that patients suffering from chronic obstructive pulmonary disease (COPD) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback